<DOC>
	<DOCNO>NCT00784589</DOCNO>
	<brief_summary>Pemphigus severe sometimes life-threatening disease mortality rate 5 10 percent depend severity disease age patient . The standard care high dos corticosteroid ( CS ) ( usually , prednisone , 1 1.5. mg/kg/day , often associate immunosuppressive drug i.e. , azathioprine , mycophenolate mofetil , cyclophosphamide , cyclosporine , although one randomise study demonstrate superiority combination corticosteroid immunosuppressive drug compare corticosteroid alone ( 9 ) . Because low frequency disease , control trial difficult conduct . Evaluation different treatment regimen propose , ; e ; corticosteroid alone , CS immunosuppressive drug , IV immunoglobulins new therapeutic regimen rituximab ( anti-CD20 monoclonal antibody direct B- lymphocyte ) immunoadsorbtion .</brief_summary>
	<brief_title>Comparison Between Rituximab Treatment General Corticotherapy Treatment Patients With Pemphigus</brief_title>
	<detailed_description />
	<mesh_term>Pemphigus</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>age &gt; =18 &lt; = 80years consent obtain patient effective female contraceptive method woman procreate age new case pemphigus vulgaris ( PV ) pemphigus foliaceus ( PF ) pemphigus vulgaris ( PV ) pemphigus foliaceus ( PF ) treat pregnant woman nurse mother woman able baby without contraception clinical trial period age &lt; 18 &gt; 80 karnovsky &lt; 50 % serious antecedent allergy anaphylactic reaction human monoclonal antibody patient depletion lymphocytic treatment next month unstable angina ischemic heart disease cardiac insufficiency cardiac rhythm trouble uncontrolled positive HIV serology positive hepatitis B / C serology consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Corticoth√©rapy</keyword>
	<keyword>Rituximab</keyword>
	<keyword>therapeutic efficacity</keyword>
	<keyword>therapeutic tolerance</keyword>
</DOC>